-
平臺編號：bio-69070
-
國際編號：CRL-2375?
-
細胞信息： AT3B-1
-
規(guī)格：frozen
-
用途：ATCC原裝細胞
-
服務費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
AT3B-1
器官來源：前列腺
細胞形態(tài)：上皮樣
是否是腫瘤細胞：0
物種來源：褐鼠
年限：22 months
運輸方式：凍存運輸
數(shù)量：大量
品系：Copenhagen
ATCC Number：CRL-2375?
相關(guān)疾?。浩渌膊?br /> 規(guī)格：0.5mg Designations: AT3B-1
Depositors: ?KJ Pienta
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Organism: Rattus norvegicus deposited as rat
Morphology:epithelial
Source: Organ: prostate
Strain: Copenhagen
Disease: malignant carcinoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Age: 22 months
Gender: male
Comments:AT3B-1 was derived from the AT-3 cell line. AT-3 was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. [39920 ]
The parental cells were grown in increasing concentrations of the drug doxorubicin until the final concentration of 0.001 mM was achieved.
These cells express a multidrug (MDR) resistant phenotype. They are more resistant to vinblastine compared to controls.
When P-glycoprotein was blocked, the AT3 B-1 cell line demonstrated drug efflux pump activity. Injection of AT3 B-1 cells into rats followed by doxorubicin treatment produced larger tumors compared to the parental controls. [39921 ]
This cell line can be used to study chemotherapy resistance in prostate cancer.
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.001 mM doxorubicin, 90%; fetal bovine serum, 10%
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 39920: Isaacs JT, et al. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281, 1986. PubMed: 3774632
39921: Replogle-Schwab TS, et al. Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer Res. 17: 4535-4538, 1997. PubMed: 9494564
細胞形態(tài)：上皮樣
是否是腫瘤細胞：0
物種來源：褐鼠
年限：22 months
運輸方式：凍存運輸
數(shù)量：大量
品系：Copenhagen
ATCC Number：CRL-2375?
相關(guān)疾?。浩渌膊?br /> 規(guī)格：0.5mg Designations: AT3B-1
Depositors: ?KJ Pienta
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Organism: Rattus norvegicus deposited as rat
Morphology:epithelial
Source: Organ: prostate
Strain: Copenhagen
Disease: malignant carcinoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Age: 22 months
Gender: male
Comments:AT3B-1 was derived from the AT-3 cell line. AT-3 was derived from a adult malignant rat prostate tumor obtained from a 22 month old inbred Copenhagen rat by Isaacs et al. [39920 ]
The parental cells were grown in increasing concentrations of the drug doxorubicin until the final concentration of 0.001 mM was achieved.
These cells express a multidrug (MDR) resistant phenotype. They are more resistant to vinblastine compared to controls.
When P-glycoprotein was blocked, the AT3 B-1 cell line demonstrated drug efflux pump activity. Injection of AT3 B-1 cells into rats followed by doxorubicin treatment produced larger tumors compared to the parental controls. [39921 ]
This cell line can be used to study chemotherapy resistance in prostate cancer.
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 0.001 mM doxorubicin, 90%; fetal bovine serum, 10%
Temperature: 37.0°C
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: Culture medium, 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 39920: Isaacs JT, et al. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261-281, 1986. PubMed: 3774632
39921: Replogle-Schwab TS, et al. Development of doxorubicin resistant rat prostate cancer cell lines. Anticancer Res. 17: 4535-4538, 1997. PubMed: 9494564
